|Company Name||Co-Diagnostics, Inc.|
|Class Period||February 25, 2020 to May 15, 2020|
|Lead Plaintiff Motion Deadline||August 17, 2020|
On February 24, 2020, Co-Diagnostics announced that it had received regulatory clearance to sell its COVID-19 tests in the European Community.
Then on April 6, 2020, the Company announced that it had received emergency use authorization for its tests from the U.S. Food and Drug Administration ("FDA").
Finally, on May 14, 2020, after the Company continued to uphold its statements about the success of its test in its first quarter results, public reports began to circulate, questioning the Company’s claims of 100% accuracy because the Company was hesitant to participate in U.S.-based testing. Later in the day, the U.S. FDA stated publicly that no COVID-19 test is 100% accurate.
On this news, the Company’s share price fell $5.06, or over 22%, to close at $17.07 per share on May 15, 2020, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Co-Diagnostics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.